Gemcitabine and interferon-α2b in solid tumors: A phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer

Anti-Cancer Drugs

Volumn 13, Issue 9, 2002, Pages 899-905

  Fuxius, Stefan ^a   Mross, Klaus ^a   Mansouri, Kambiz ^b   Unger, Clemens ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Gemcitabine; Immunotherapy; Interferon; Phase I; Solid tumors

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; GEMCITABINE; INTERFERON; RECOMBINANT ALPHA2B INTERFERON; ALPHA2B INTERFERON; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY CANCER; LEUKOCYTE COUNT; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; CANCER STAGING; INTRAVENOUS DRUG ADMINISTRATION; KARNOFSKY PERFORMANCE STATUS; KIDNEY TUMOR; LUNG TUMOR; MIDDLE AGED; OVARY TUMOR; PANCREAS TUMOR; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; KARNOFSKY PERFORMANCE STATUS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0036813368     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200210000-00001     Document Type: Article

References (28)

1. Hertel LW, Kroin JS, Misner JW, et al. Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 1988; 53: 2406-9.
2. Carmichael J. The role of gemcitabine in the treatment of other tumours. Br J Cancer 1998; 78(suppl 3): 21-5.
3. Le Chevalier T, Gottfried M, Gatzemeier U, et al. A phase II multicenter study of gemcitabine in non small cell lung cancer. Bull Cancer 1997; 84: 282-8.
4. Kirste T, Hauns B, Eichelmann A, et al. Complete remission in patients with pancreatic cancer: A rare but sometimes achievable event. Onkologie 1998; 21: 64-6.
5. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. Cancer 1996; 78(suppl 3): 633-8.
6. von der Maase H. Gemcitabine in advanced bladder cancer. Semin Oncol 2001; 28(2 suppl 7): 11-4.
7. Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Huntingt) 2001; 15(2 suppl 3): 11-4.
8. Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M. Phase II study of gemcitabine in previously-treated ovarian cancer patients. Anti-Cancer Drugs 1995; 6(suppl 6): 61-2.
9. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 543-7.
10. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
11. Aapro MS, Martin C, Hatty S. Gemcitabine - A safety review. Anti-Cancer Drugs 1998; 9: 191-201.
12. Fuxius S, Unger C, Mross K. Pulmonary toxicity resulting from treatment with gemcitabine. Onkologie 1999; 22: 146-9.
13. Taylor JL, Grossberg SE. Recent progress in interferon research: Molecular mechanisms of regulation, action, and virus circumvention. Virus Res 1990; 15: 1-26.
14. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56: 727-77.
15. Greenberg SB. Human interferon in viral diseases. Infect Dis Clin N Am 1987; 1: 383-423.
16. Faltynek CR, Kung HF. The biochemical mechanisms of action of the interferons. Biofactors 1998; 1: 227-35.
17. Hicks NJ, Morris AG, Burke DC. Partial reversion of the transformed phenotype of murine sarcoma virus-transformed cells in the presence of interferon: A possible mechanism for the anti-tumour effect of interferon. J Cell Sci 1981; 49: 225-36.
18. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984; 2: 336-52.
19. Spiegel RJ. Alpha interferons: A clinical review. Urology 1989; 34(suppl 4): 75-9.
20. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994; 10: 115-50.
21. Rohde D, Hayn HK, Blatter J, Jakse G. The efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines. Int J Oncol 1998; 12: 1361-6.
22. Rohde D, Goertz M, Blatter J, Jakse G. The efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma. Int J Oncol 1998; 12: 1367-72.
23. EEC note for guidance: Good clinical practice for trials on medicinal products in the European community. CPMP Working Party on Efficacy of Medicinal Products. Pharmacol Toxicol 1990; 67: 361-72.
24. Arthur CK, Ma DD. Combined interferon alfa-2α and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol 1993; 89(suppl 1): 15-21.
25. Rodriguez-Villanueva J, McDonnell TJ. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-α. Int J Cancer 1995; 61: 110-4.
26. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61(suppl 1): 3-13.
27. De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: A phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996; 37: 491-5.
28. Rohde D, Thiemann D, Wildberger J, Wolff J, Jakse G. Treatment of renal cancer patients with gemcitabine (2′,2′-difluorodeoxycytidine) and interferons: Antitumor activity and toxicity. Oncol Rep 1998; 5: 1555-60.